Zobrazeno 1 - 10
of 52
pro vyhledávání: '"M. Looijen"'
Autor:
Annette H M van der Helm-van Mil, Pascal H P de Jong, Paco M J Welsing, Ilja Tchetverikov, Jolanda J Luime, Marijn Vis, Marc R Kok, Paul Baudoin, Lindy-Anne Korswagen, Selinde V J Snoeck Henkemans, Agnes E M Looijen, Gonul Hazal Koc
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presen
Externí odkaz:
https://doaj.org/article/0be597d25ac94e5d84273f456525241c
Publikováno v:
European Respiratory Review, Vol 19, Iss 116, Pp 165-168 (2010)
Externí odkaz:
https://doaj.org/article/e385956cbddd47e6bb14c4947a099b52
Autor:
Annette H M van der Helm-van Mil, Pascal H P de Jong, Elise van Mulligen, Agnes E M Looijen, Judith W Heutz
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Externí odkaz:
https://doaj.org/article/778fe9394b394109a6b50b267244aea0
Autor:
Annette H M van der Helm-van Mil, Pascal H P de Jong, Marijn Vis, Selinde V J Snoeck Henkemans, Agnes E M Looijen
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective To compare clinical and patient-reported outcomes (PROs) over 5 years between patients with rheumatoid arthritis (RA) in sustained remission (sREM), sustained low disease activity (sLDA) or active disease (AD) in the first year after diagno
Externí odkaz:
https://doaj.org/article/e04c07e093c7483e80d62608f1e8515a
Autor:
Agnes E M Looijen, Reinier C A van Linschoten, Jan-Dietert Brugma, Dirk Jan Hijnen, Pascal H P de Jong, P Hugo M van der Kuy, Jan A M van Laar, C Janneke van der Woude, Annelieke Pasma
Publikováno v:
JMIR Research Protocols, Vol 12, p e43230 (2023)
BackgroundDespite enormous clinical improvements, due to better management strategies and the availability of biologicals, immune-mediated inflammatory diseases (IMIDs) still have a significant impact on patients’ lives. To further reduce disease b
Externí odkaz:
https://doaj.org/article/1cca65316fee46fb81caf878bdb55c49
Autor:
H.J.M. Groen, E. Schuuring, W. Timens, A. van den Berg, T.J.N. Hiltermann, A-M.C. Dingemans, E.J.M. Speel, B.E. van den Borne, S. Riemersma, J. Staal-van den Brekel, A.J. de Langen, M. Looijen-Salamon, E.H.F.M. van der Heijden, L. Hendriks, M.F. Mastik, N. Werner, N. 't Hart, R. Pelgrim, A.J. van der Wekken
Purpose: ALK rearrangement detection using FISH is the standard test to identify patients with non–small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c79880285ef78a4272ebf4f2756db36
https://doi.org/10.1158/1078-0432.c.6526752
https://doi.org/10.1158/1078-0432.c.6526752
Autor:
H.J.M. Groen, E. Schuuring, W. Timens, A. van den Berg, T.J.N. Hiltermann, A-M.C. Dingemans, E.J.M. Speel, B.E. van den Borne, S. Riemersma, J. Staal-van den Brekel, A.J. de Langen, M. Looijen-Salamon, E.H.F.M. van der Heijden, L. Hendriks, M.F. Mastik, N. Werner, N. 't Hart, R. Pelgrim, A.J. van der Wekken
Percentage of nuclei considered as ALK positive based on ALK-FISH in the screening cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::700ee52754fe4872bc5e6a3b61c94e7a
https://doi.org/10.1158/1078-0432.22467804.v1
https://doi.org/10.1158/1078-0432.22467804.v1
Autor:
H.J.M. Groen, E. Schuuring, W. Timens, A. van den Berg, T.J.N. Hiltermann, A-M.C. Dingemans, E.J.M. Speel, B.E. van den Borne, S. Riemersma, J. Staal-van den Brekel, A.J. de Langen, M. Looijen-Salamon, E.H.F.M. van der Heijden, L. Hendriks, M.F. Mastik, N. Werner, N. 't Hart, R. Pelgrim, A.J. van der Wekken
In this file a description of all used ALK-FISH and ALK-IHC tests have been put together with table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59843b388f600282e24fce42a1d3916d
https://doi.org/10.1158/1078-0432.22467801
https://doi.org/10.1158/1078-0432.22467801
Publikováno v:
Rheumatology (Oxford, England), 61(8), e216-e218. Oxford University Press
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b603e533ce98cf81e269df94deb2e95
http://www.scopus.com/inward/record.url?scp=85135597604&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85135597604&partnerID=8YFLogxK
Autor:
Agnes E M Looijen, Reinier C A van Linschoten, Jan-Dietert Brugma, Dirk Jan Hijnen, Pascal H P de Jong, P Hugo M van der Kuy, Jan A M van Laar, C Janneke van der Woude, Annelieke Pasma
BACKGROUND Despite enormous clinical improvements, due to better management strategies and the availability of biologicals, immune-mediated inflammatory diseases (IMIDs) still have a significant impact on patients’ lives. To further reduce disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6653190d29992b13925e3e48cbb4550c
https://doi.org/10.2196/preprints.43230
https://doi.org/10.2196/preprints.43230